Teladoc Health Adds AI Tools as Shares Stay Under Pressure

October 18, 2026 - 15:39

Teladoc Health (TDOC) has introduced two artificial intelligence tools inside its Solo platform, SoloVitals and SoloScribe, designed to support contactless vital sign tracking and reduce the documentation burden on clinicians. The company is pitching the tools at hospital and health system clients, positioning them as a way to make virtual care visits run more smoothly for both patients and staff.

The product news arrives against a difficult backdrop for the stock. Teladoc shares have fallen 10 percent over the past 30 days, and the 90-day return sits at a decline of 41.24 percent. Over five years, the total shareholder return has dropped 95.88 percent, a figure that points to persistent longer term weakness rather than a short term dip.

That split between product momentum and share price performance is the central question for investors. The new AI features could help Teladoc deepen relationships with large health systems and differentiate its virtual care offering in a crowded market. But the market has so far shown little willingness to reward the rollout, and the steep multi-year decline suggests concerns about growth and profitability remain unresolved.

Whether the AI tools translate into measurable client adoption and revenue will matter more than the announcement itself. For now, the stock is cheap by some measures, but the weak price trend shows investors are still waiting for evidence that the business can turn its technology investments into durable financial results.